LYEL stock forecast, quote, news & analysis
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors... Show more
Why Lyell Immunopharma (LYEL) Is Up +20% in the Last 30 Days
Key Takeaways
- LYEL stock surged +20% over the last 30 days, driven by a $50 million equity funding tranche and positive clinical pipeline momentum.
- Over the past quarter, the stock rose +1%, reflecting steady biotech sector sentiment amid ongoing trial advancements.
- Key catalysts include initiation of a Phase 3 CAR T-cell trial and Q4 earnings highlighting cash runway extension.
- Improved net losses in recent quarters signal operational progress in cell therapy development.
- Investor focus remains on upcoming clinical data readouts and conference presentations.
Lyell Immunopharma (LYEL) Company Overview and Market Position
Lyell Immunopharma, Inc. is a clinical-stage cell therapy company developing next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. Its core business model centers on innovative platforms like c-Jun overexpression and gene edits to create durable, stem-like CAR T-cells that overcome limitations of current therapies, such as exhaustion and poor persistence.
In the competitive biotechnology landscape, Lyell differentiates through its multi-specific CAR T products, including lead candidate rondecabtagene autoleucel (ronde-cel), targeting CD19/CD20 for large B-cell lymphoma (LBCL). The company's focus on both blood cancers and solid tumors positions it amid giants like Bristol Myers Squibb and Gilead, but with proprietary tech addressing key unmet needs. Recent stock behavior aligns with its cash bolstering via funding, supporting pipeline execution amid biotech volatility.
Lyell Immunopharma (LYEL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, LYEL stock climbed +20%, moving from approximately $20 to $24 in a steady uptrend with moderate volatility. The gain reflects consistent buying interest rather than sharp spikes.
For the past quarter, the stock edged up +1%, trading in a relatively flat range around $24 after minor fluctuations. This range-bound movement indicates stabilization following earlier-year volatility, with low single-digit gains amid broader market trends.
What Drove LYEL Stock Price in the Last 30 Days
The +20% rally stemmed primarily from a March equity private placement closing an additional $50 million tranche, triggered by a clinical milestone achievement. This funding, part of a larger deal, extended the company's cash runway and appointed a new chief financial officer, boosting investor confidence in execution.
Q4 2025 earnings, despite a reported net loss of $140.7 million and an earnings per share (EPS) miss, highlighted pipeline progress including dosing in a first-of-its-kind Phase 3 head-to-head CAR T-cell trial for LBCL. Conference participations further amplified positive sentiment around ronde-cel data. Biotech sector tailwinds, including interest in innovative cell therapies, supported the upmove without major analyst upgrades.
What Drove LYEL Stock Performance Over the Last Quarter
The modest +1% quarterly gain built on sustained narratives around clinical advancements and financial prudence. Initiation of patient dosing in the pivotal Phase 3 PiNACLE-H2H trial for second-line LBCL provided a key catalyst, underscoring competitive positioning against standard CAR T therapies.
Macro factors like stabilizing interest rates aided small-cap biotechs, while institutional accumulation rewarded pipeline milestones. Q3 2025 results showed reduced net losses, signaling cost efficiencies. Cumulative impacts from American Society of Hematology (ASH) data presentations on durable responses in LBCL reinforced long-term potential, offsetting EPS pressures and driving range-bound stability.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from among hundreds that trade thousands of tickers across various markets. These curated bots employ diverse strategies, such as trend-following, mean reversion, or momentum plays, across short-term day trades to longer swings, with performance metrics including win rates, profit factors, and Sharpe ratios. Updated in real-time, the section highlights bots most relevant to current market conditions, helping traders identify tools aligned with their risk tolerance and goals. Explore Trending AI Robots to integrate AI into your stock analysis workflow.
LYEL Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming clinical trial data from the Phase 3 PiNACLE-H2H study and Phase 1 LYL273 for colorectal cancer, as readouts could sway sentiment. Next quarterly earnings will detail cash burn and R&D spend amid the extended runway.
Biotech sector trends, regulatory feedback on CAR T approvals, and macroeconomic shifts like Federal Reserve policy on rates remain influential. Strategic developments, including potential partnerships or ImmPACT Bio acquisition integration, alongside pipeline expansions, pose both catalysts and risks in this high-volatility space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
LYEL's Stochastic Oscillator slumps oversold zone
The Stochastic Oscillator for LYEL moved into oversold territory on June 22, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for LYEL's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Moving Average Convergence Divergence (MACD) for LYEL just turned positive on June 15, 2026. Looking at past instances where LYEL's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LYEL advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .
LYEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for LYEL moved below the 200-day moving average on May 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LYEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for LYEL entered a downward trend on June 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LYEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.020) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). LYEL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). LYEL's P/S Ratio (10000.000) is very high in comparison to the industry average of (367.026).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology